Patents by Inventor René Toes

René Toes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10684284
    Abstract: The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 16, 2020
    Assignees: Inova Diagnostics, Inc., Leiden University Medical Center
    Inventors: Michael Mahler, Leendert A. Trouw, Jan Wouter Drijfhout, Tom Huizinga, René Toes, Peter Van Veelen
  • Patent number: 9829489
    Abstract: The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: November 28, 2017
    Assignees: INOVA DIAGNOSTICS, INC., LEIDEN UNIVERSITY MEDICAL CENTER
    Inventors: Michael Mahler, Leendert A Trouw, Jan Wouter Drijfhout, Tom Huizinga, René Toes, Peter Van Veelen
  • Publication number: 20090285814
    Abstract: Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a peptide tumor vaccine, or for otherwise activating CTLs so that the activated CTLs can act against tumorous or infected cells. The CD40 binding molecules can include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, as well as other molecules including peptides, oligonucleotides, peptidomimetics and organic compounds which bind to CD40 and activate the CTL response.
    Type: Application
    Filed: July 17, 2009
    Publication date: November 19, 2009
    Applicant: University Hospital Leiden
    Inventors: Cornelis J. M. Melief, Stephen P. Schoenberger, Rienk Offringa, Rene Toes
  • Patent number: 7563445
    Abstract: Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a peptide tumor vaccine, or for otherwise activating CTLs so that the activated CTLs can act against tumorous or infected cells. The CD40 binding molecules can include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, (Fab?)2 and Fv, as well as other molecules including peptides, oligonucleotides, peptidomimetics and organic compounds which bind to CD40 and activate the CTL response.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: July 21, 2009
    Assignee: Keygene N.V.
    Inventors: Cornelis J. M. Melief, Stephen P. Schoenberger, Rienk Offringa, Rene Toes
  • Publication number: 20090117584
    Abstract: Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis).
    Type: Application
    Filed: June 29, 2006
    Publication date: May 7, 2009
    Applicant: GENMAB A/S
    Inventors: Rene Toes, Thomas Huizinga, Miranda Molenaar, Paul Parren, Jan Van De Winkel
  • Publication number: 20070292449
    Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.
    Type: Application
    Filed: February 28, 2007
    Publication date: December 20, 2007
    Applicant: Academisch Ziekenhuis Leiden
    Inventors: Sjoerd Van Der Burg, Tom Ottenhoff, Annemieke Geluk, Maria Schoenmaekers-Welters, Annemieke De Jong, Rienk Offringa, Cornelis Melief, Rene Toes
  • Publication number: 20050255106
    Abstract: Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition comprises an agonistic anti-CD40 antibody or a fragment thereof, and/or an agonistic anti-4-1BB antibody or a fragment thereof. The agonistic antibody molecules include fragments like Fab, (Fab?)2 and Fv. The methods and compositions may further comprise polypeptides or nucleic acid sequences having or encoding a class 1 MHC or class II MHC-resisted T cell epitope.
    Type: Application
    Filed: April 4, 2003
    Publication date: November 17, 2005
    Inventors: Linda Diehl, Geertje Van Mierlo, Cornelis Melief, Rene Toes, Rienk Offringa
  • Publication number: 20030118588
    Abstract: Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition comprises an agonist anti-CD40 antibody or a fragment thereof. The anti-CD40 antibody molecules include fragments like Fab, (Fab′)2 and Fv. The composition can also include an agonistic anti-4-1BB antibody or fragment thereof.
    Type: Application
    Filed: April 4, 2002
    Publication date: June 26, 2003
    Inventors: Linda Diehl, Geertje van Mierlo, Robert S. Mittler, Cornelis J.M. Melief, Rene Toes, Rienk Offringa
  • Publication number: 20030022860
    Abstract: Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a peptide tumor vaccine, or for otherwise activating CTLs so that the activated CTLs can act against tumorous or infected cells. The CD40 binding molecules can include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, (Fab′)2 and Fv, as well as other molecules including peptides, oligonucleotides, peptidomimetics and organic compounds which bind to CD40 and activate the CTL response.
    Type: Application
    Filed: August 26, 2002
    Publication date: January 30, 2003
    Inventors: Cornelis J.M. Melief, Stephen P. Schoenberger, Rienk Offringa, Rene Toes